Introduction: The interplay between HIV and cysticercosis in co-endemic regions remains poorly understood, particularly regarding the immune responses but is relevant for an effective treatment strategy. This study aimed to investigate the relationship between peripheral cytokine profiles, CD4 T-cell counts, and cysticercosis infection status in HIV-positive individuals in Tanzania's southern highlands.
Methods: We conducted a cross-sectional study involving 110 HIV-positive individuals. Cysticercosis was diagnosed using antibody and antigen tests, with neurocysticercosis confirmed by CT imaging. CD4 counts and serum cytokine levels (pro- and anti-inflammatory) were analyzed using multivariate regression and MANOVA, including sex-stratified analyses.
Results: Among participants, 20.9% tested positive for cysticercosis antibodies, 43.6% for antigens and 20.2% presented with brain cysts, with 10.6% showing active neurocysticercosis. Cysticercosis-positive individuals showed positive correlations between CD4 counts and pro-inflammatory cytokines (e.g., TNF-α, IL-1β), contrasting with negative correlations in cysticercosis-negative individuals. Sex-stratified analysis showed stronger regulatory cytokine responses in males compared to females, particularly involving higher levels of IL-10 and IL-4 indicating sex-specific immune modulation in co-infected individuals. However, overall cytokine profiles were not significantly influenced by CD4 categories or cysticercosis status.
Conclusion: These results contribute to our understanding of immunological interactions in HIV-cysticercosis co-infection and underscore the need for further research with larger sample sizes to elucidate the clinical implications of these findings. Such studies could inform the development of more effective, sex-personalized treatment strategies for HIV patients in cysticercosis-endemic regions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880214 | PMC |
| http://dx.doi.org/10.3389/fimmu.2025.1521295 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
T-cell Engagers in Prostate Cancer.
Eur Urol
March 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents).
View Article and Find Full Text PDFIn situ global mapping of protein perturbations via protein abundance and conformation analysis.
Anal Chim Acta
May 2025
State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing, 211198, China. Electronic address:
Background: Traditional studies of protein responses to external stimuli primarily focus on changes in protein abundance, often overlooking the critical role of protein conformational alterations. To address this gap, we developed Protein Abundance and Conformation Analysis (PACA), an integrative method that quantifies both protein abundance and conformational changes. PACA combines conventional quantitative proteomics for abundance measurements with Target Response Accessibility Profiling (TRAP), a technique that captures conformational changes in situ by applying reductive dimethylation to label accessible lysine residues in living cells before lysis.
View Article and Find Full Text PDFExploring new horizons in allergic contact dermatitis treatment: the role of emerging therapies.
Actas Dermosifiliogr
March 2025
Contact Eczema and Immunoallergic Diseases Department. Dermatology, Spain; Dermatology Department. Hospital Universitario San Cecilio, Granada. Spain; Instituto de Investigación Biosanitaria ibs, Granada, Spain. Electronic address:
The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes treatment challenging. With advances in the understanding of the cellular and molecular pathogenesis of this dermatosis, new therapeutic options are emerging. In particular, the use of biologic drugs such as dupilumab and small molecule inhibitors, such as JAK inhibitors have gained momentum given the cross-cutting inhibition of multiple cytokine actions.
View Article and Find Full Text PDFA machine learning-based prognostic signature utilizing MSC proteomics for predicting bladder cancer prognosis and treatment response.
Transl Oncol
March 2025
Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Urological Clinical Center, Lanzhou, China. Electronic address:
Background: Mesenchymal stem cells (MSCs), due to their tumor-targeting homing properties, are present in the tumor microenvironment (TME) and influence the biological behaviors of tumors. The purpose of this paper is to establish a signature based on the MSC secretome to predict the prognosis and treatment of bladder cancer (BLCA).
Methods: The presence of MSCs in BLCA was validated through flow cytometry and multiplex fluorescence immunohistochemistry (mFIHC), and the relationships between MSCs and clinical characteristics were explored.
Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines.
J Immunol
February 2025
Vaccine Research Institute, Université Paris-Est Créteil, Créteil, France.
The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara (MVA) Bavarian Nordic or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody responders was higher among MPXV-infected individuals than MVA vaccinees.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!